Replies to post #95403 on NorthWest Biotherapeutics Inc (NWBO)

[Savage39]

That's odd that Jerry jasinowski just bought 1.2 mil shares if they are gonna get sued for hiding futility. You are reaching bro

[sentiment_stocks]

No wonder you remember it... it was a very expensive course in statistics for you.

http://www.investorvillage.com/smbd.asp?mb=1195&pt=m&AuthoredBy=AVII77

Msg 8439 of 10178 at 3/29/2010 8:42:40 PM by

AVII77

Well, that was an expensive short course in statistics
Thanks to all who helped me learn the science and math involved.
and, regardless of the results, I am grateful for the trial participants who were willing to contribute in the hope of helping those who follow after them.

[chinatown1980]

"Mr Haiber, I recognize that name. He successfully defended Genvec when they were sued by investors after their PACT trial was stopped for futility (I remember that black Monday well)."

Thanks for sharing. This is one of the more interesting pieces of information as of late. I don't think it is a coincidence he was chosen to defend the company.

[AVII77]

after their PACT trial was stopped for futility (I remember that black Monday well).

Censoring and "missing Data" played a central role in my failure to correctly assess the risk in that trial and caused me to misinterpret the delay in the interim being triggered as positive. There too "everyone was living longer".

Senti reposting my comments from that fateful day reminded me of a quote from a favorite book:

“We choose our next world through what we learn in this one. Learn nothing, and the next world is the same as this one, all the same limitations and lead weights to overcome.”

In that spirit, folks here should know about how missing data will be handled in the DCVax Phase 3 trial.

The following types of patients will not count as a progression event in this trial:

A Treatment discontinuation for undocumented progression,
B Treatment discontinuation for toxicity or other reason,
C New anticancer treatment started prior to documented progression,
D Progression after more than one missed visit,
E Death after more than two missed visits.

Understanding the way missing data is handled in a clinical trial is important.